Kymera Therapeutics (KYMR) EBITDA (2019 - 2026)

Kymera Therapeutics (KYMR) has 8 years of EBITDA data on file, last reported at -$84.2 million in Q1 2026.

• On a quarterly basis, EBITDA fell 13.07% year-over-year to -$84.2 million in Q1 2026; TTM through Mar 2026 was -$359.1 million, a 29.08% decrease from a year earlier, with the FY2025 full-year figure at -$349.4 million, down 33.54% from the prior year.
• EBITDA for Q1 2026 stood at -$84.2 million, up from -$97.9 million in the prior quarter.
• Over the last five years, EBITDA for KYMR reached as high as -$19.3 million in Q4 2023 and fell as low as -$97.9 million in Q4 2025.
• Historically, EBITDA has averaged -$60.1 million across 5 years, with a median of -$57.5 million in 2023.
• Across the five-year window, EBITDA soared 50.01% in 2023 and plunged 318.16% in 2024, its largest moves.
• Year by year, EBITDA stood at -$38.6 million in 2022, then surged by 50.01% to -$19.3 million in 2023, then plunged by 318.16% to -$80.8 million in 2024, then fell by 21.23% to -$97.9 million in 2025, then increased by 14.04% to -$84.2 million in 2026.
• Per Business Quant data, the three most recent EBITDA figures were -$84.2 million in Q1 2026, -$97.9 million in Q4 2025, and -$92.5 million in Q3 2025.